Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Ben-Salem S, Hu Q, Liu Y, Alshalalfa M, Zhao X, Wang I, et al. Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes. Eur Urol Open Sci. 2020;22:34-44.

Roytman M, Pisapia DJ, Liechty B, Lin E, Skafida M, Magge RS, et al. Somatostatin receptor-2 negative meningioma: pathologic correlation and imaging implications. Clin Imaging. 2020;66:18-22.

Haider S, Tyekucheva S, Prandi D, Fox NS, Ahn J, Xu AW, et al. Systematic Assessment of Tumor Purity and Its Clinical Implications. JCO Precis Oncol. 2020;4.

Vossoughi S, Fischkoff K, DeSimone RA, Schwartz J. Blood stewardship: conservation and supply of blood components during the severe acute respiratory syndrome coronavirus 2 pandemic. Transfusion. 2020;60(9):2156-2158.

Laginestra MA, Cascione L, Motta G, Fuligni F, Agostinelli C, Rossi M, et al. Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified. Mod Pathol. 2020;33(2):179-187.

Chan KK, Magro C, Shoushtari A, Rudin C, Rotemberg V, Rossi A, et al. Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature. Oncologist. 2020;25(2):140-149.

Fischer K, Fenzl A, Liu D, Dyar KA, Kleinert M, Brielmeier M, et al. The scaffold protein p62 regulates adaptive thermogenesis through ATF2 nuclear target activation. Nat Commun. 2020;11(1):2306.

Scholze H, Stephenson RE, Reynolds R, Shah S, Puri R, Butler SD, et al. Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes. Blood Adv. 2020;4(20):5226-5231.

Verma A, Muthukumar T, Yang H, Lubetzky M, Cassidy MF, Lee JR, et al. Urinary cell transcriptomics and acute rejection in human kidney allografts. JCI Insight. 2020;5(4).

Kaur H, Samarska I, Lu J, Faisal F, Maughan BL, Murali S, et al. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance. Prostate. 2020;80(12):1012-1023.